Page 26«..1020..25262728..4050..»

MDxHealth Reports Q2 and Half Year 2024 Results

Posted: August 22, 2024 at 2:32 am

MDxHealth Reports Q2 and Half Year 2024 Results

Read more here:
MDxHealth Reports Q2 and Half Year 2024 Results

Posted in Global News Feed | Comments Off on MDxHealth Reports Q2 and Half Year 2024 Results

SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®

Posted: August 22, 2024 at 2:32 am

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced a new contract with the U.S. Department of Defense (DOD) for the procurement of approximately $9 million of TPOXX® (Contract number: W911SR24C0030). This award is comprised primarily of oral TPOXX®, with a small amount of intravenous (IV) TPOXX®, and represents the third procurement contract award from the DOD over the past three years.

Read more here:
SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®

Posted in Global News Feed | Comments Off on SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment

Posted: August 22, 2024 at 2:32 am

Vancouver, Canada, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received a new patent approval from the United States Patent and Trademark Office, marking another significant advancement in its proprietary MEAI-based binge behavior regulator program.

Read more from the original source:
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment

Posted in Global News Feed | Comments Off on Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment

Certara to Participate in Upcoming Investor Conferences

Posted: August 22, 2024 at 2:32 am

RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:

Follow this link:
Certara to Participate in Upcoming Investor Conferences

Posted in Global News Feed | Comments Off on Certara to Participate in Upcoming Investor Conferences

Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility

Posted: August 22, 2024 at 2:32 am

Certification Emphasizes Unwavering Commitment to Quality and Is an Essential Step for U.S. Clinical Market Entry Certification Emphasizes Unwavering Commitment to Quality and Is an Essential Step for U.S. Clinical Market Entry

Read the original:
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility

Posted in Global News Feed | Comments Off on Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility

Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of…

Posted: August 22, 2024 at 2:32 am

Advancing Pharmaceutical Innovation: Brains Bioceutical’s CEP Certification will Streamline Cannabinoid Drug Development, Inspired by Jazz Pharmaceuticals’ CBD-Based Epilepsy Drug and 2024 $1.4 Billion Revenue Projection Advancing Pharmaceutical Innovation: Brains Bioceutical’s CEP Certification will Streamline Cannabinoid Drug Development, Inspired by Jazz Pharmaceuticals’ CBD-Based Epilepsy Drug and 2024 $1.4 Billion Revenue Projection

Read this article:
Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of...

Posted in Global News Feed | Comments Off on Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of…

Bavarian Nordic Announces First Half 2024 Results

Posted: August 22, 2024 at 2:32 am

COPENHAGEN, Denmark, August 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first half of 2024 and released its financial calendar for 2025.

Go here to see the original:
Bavarian Nordic Announces First Half 2024 Results

Posted in Global News Feed | Comments Off on Bavarian Nordic Announces First Half 2024 Results

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Posted: August 14, 2024 at 2:37 am

Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs

Read the rest here:
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Posted in Global News Feed | Comments Off on Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

Posted: August 14, 2024 at 2:37 am

– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML –

Go here to read the rest:
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

Posted in Global News Feed | Comments Off on Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Posted: August 14, 2024 at 2:37 am

– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis –

Read the original:
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Posted in Global News Feed | Comments Off on Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Page 26«..1020..25262728..4050..»